 The European Commission EC has approved Albireo Pharma Incs NASDAQ: ALBO Bylvay odevixibat for all subtypes of progressive familial intrahepatic cholestasis PFIC. Bylvay is a potent, non-systemic ileal bile acid transport inhibitor IBATi. 